Skip to main content
. 2022 Mar 14;20:1306–1344. doi: 10.1016/j.csbj.2022.03.009

Fig. 9.

Fig. 9

Available structures for SARS-CoV-2 Mpro inhibitors evaluated in vivo and in clinical trials.